1002.3000 -9.40 (-0.93%)
NSE Jul 09, 2025 15:31 PM
Volume: 46,626
 

1002.30
-0.93%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended